<DOC>
	<DOCNO>NCT01631877</DOCNO>
	<brief_summary>After successful screening case cirrhosis liver irrespective etiology non tumor portal vein thrombosis enrol . The baseline Doppler parameter record patient randomize either interventional ( acenocoumarol ) placebo group along first five day subcutaneous Low Molecular Weight Heparin inj . Enoxaparin interventional arm placebo injection control arm . Every 3 monthly Doppler screen recanalization portal vein thrombus do monitoring International Normalized Ratio ( INR ) target INR 2-3 . Both group receive therapy one year irrespective Doppler finding relation portal vein thrombus re-canalization.Then one year drug free monitoring do group per primary secondary outcome . .</brief_summary>
	<brief_title>Efficacy Safety Acenocoumarol Treatment Nontumor Portal Vein Thrombosis Cirrhosis Liver</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Acenocoumarol</mesh_term>
	<criteria>A clinical , radiological histologic diagnosis cirrhosis Partial total Portal vein thrombus ( evidence chronic thrombus ) Informed consent participate study Acute thrombus Portal vein Hepatocellular carcinoma malignancy , Hypercoagulable state liver disease relate DRUGS oral contraceptive , anticoagulation antiplatelet drug . Base line INR &gt; 2 Child Turcott Pugh score &gt; 11 Recent peptic ulcer disease History Hemorrhagic stroke Pregnancy . Uncontrolled Hypertension Age &gt; 70 yr Non responder betablocker require Endoscopic Variceal Ligation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>